

Discovery of Lead for a First-in-Class Drug Treating Inflammatory Bowel Disease (IBD)

IMMUNOLOGY	Lead
Product Type	Chemical Product
Indication	Inflammatory Bowel Disease
Target	Undisclosed Target
MoA(Mechanism of Action)	Inhibits a novel target to control various signaling pathways related to IBD simultaneously
Competitiveness	IBD has huge complexity raised from diverse signaling pathways differently activated according to the cause of the outbreak and the level of immune activation. Therefore, the strategies that strongly suppress a specific signaling pathway are not sufficient to treat complex diseases such as IBD and are likely to exhibit side effects. PimedBio identified a novel target to control various signaling pathways related to IBD simultaneously and discovered group of hits for the target. Moreover, two of the hits showed clear efficacy in IBD animal model. Currently, we are optimizing the hits to discover first-in-class drug candidate for IBD.
Development Stage	Lead
Route of Administration	Oral